Members of Lumitos board and management team intend to exercise warrants of series TO6

Members of the board and management that hold warrants of series TO6 Lumito AB (publ) ("Lumito" or the "Company") intend to exercise 575,512 warrants to a value of SEK 224 thousand. The board and management team intends to exercise warrants, directly or via companies, according to the following: Kerstin Jakobsson (Chair of the Board) – […]

Lumito signs Letter of Intent with Scientific Advisor

Lumito has signed a Letter of Intent with pathologist Paul Waring for strategic guidance regarding the market need for Lumito's products and future product development. Paul Waring is a highly experienced pathologist with approximately 35 years of leading and global experience in the hospital sector, academia, and industry. He initiated and drove the partnership between […]

Lumito AB signs a Letter of Intent with Katana Labs GmbH

Lumito has signed a "Letter of Intent” with Katana Labs in Germany to offer a cloud and AI-based image analysis solution to Lumito's future customers with "scanning-service agreements". For potential customers to easily evaluate Lumito's product SCIZYS, a "scanning service" is offered. This enables customers to evaluate the benefits of SCIZYS without first investing in […]

Lumito has CE-marked its first product SCIZYS

Lumito has CE-marked its first product, SCIZYS. This is an important milestone for Lumito and means that sales for the histopathological research market can begin. SCIZYS S1 now fulfils all the relevant provisions of the EC Machinery Directive 2006/42/EC. The internal work required to be able to CE mark the product after receiving the final […]

Research group at the Tyndall National Institute got an article published on the use of up-converting nanoparticles

A research group at the Tyndall National Institute in Cork, Ireland, got an article published in Biomedical Optics Express titled "High contrast breast cancer biomarker semi-quantification and immunohistochemistry imaging using upconverting nanoparticles". The research study uses Lumito's technology with up-converting nanoparticles (UCNPs). The article examines the use of UCNPs to distinguish different levels of HER2 […]

Lumito attends the Digital Pathology & AI Congress in London

On December 7–8, Lumito will exhibit with a booth at the annual Digital Pathology & AI Congress in London. The presence is part of the company's branding work within the company's primary target group ahead of the upcoming launch of SCIZYS. – It is important for us to build trust around our brand and product. […]

Lumito has started an internal pilot study for multiplexing

Lumito has started a pilot study where the aim is to investigate the possibilities of multiplexing by adding another nanoparticle label to the company's unique UCNP-based technology. There is a pronounced need from the market regarding requests for multiplexing to facilitate further and streamline the work within tissue analysis. Lumito already offers multiplexing with today's […]

First factory produced SCIZYS reagent kit is now available

The first batch of Lumito's reagent intended for end customer sales is now produced by Lumito's production partner, Uniogen Oy. Lumito has collaborated with Uniogen Oy (formerly Kaivogen Oy) for over 15 months to prepare the production of the nanoparticle-based reagent kit belonging to the company's digital pathology solution. – It feels great that a […]